Filter Results:
(925)
Show Results For
- All HBS Web
(925)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (667)
Show Results For
- All HBS Web
(925)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (667)
- August 2007 (Revised November 2008)
- Case
Biocon: Launching a New Cancer Drug in India
By: Sunil Gupta and Das Narayandas
Kiran Majumdar-Shaw, the CEO of Biocon has to make product launch timing, pricing, channel, and communications mix decisions relating to the launch of BioMAb, a new cancer drug in India. View Details
Keywords: Price; Health Care and Treatment; Marketing Strategy; Product Launch; Planning; Biotechnology Industry; Biotechnology Industry; India
Gupta, Sunil, and Das Narayandas. "Biocon: Launching a New Cancer Drug in India." Harvard Business School Case 508-026, August 2007. (Revised November 2008.)
- March 2006
- Teaching Note
Stan Lapidus: Profile of a Medical Entrepreneur (TN)
By: Robert F. Higgins, Richard G. Hamermesh and Erin Seefeld
Teaching Note to (805-087). View Details
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (B)
By: Sandra J. Sucher and Stacy McManus
When Dr. Daniel Vasella learned of the early Phase 1 trial results, he immediately decided what course of action Novartis would take. Students will be able to examine and assess the concrete steps, and the rationale behind them, that Novartis took in response to this... View Details
Keywords: Decision Making; Moral Sensibility; Innovation and Invention; Distribution; Product Development; Production; Problems and Challenges; Research and Development; Biotechnology Industry; Biotechnology Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (B)." Harvard Business School Case 603-044, April 2003. (Revised October 2004.)
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details
Keywords: Decision Making; Health Testing and Trials; Innovation and Invention; Markets; Distribution; Product Development; Production; Problems and Challenges; Research; Research and Development; Complexity; Biotechnology Industry; Biotechnology Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
- December 2002
- Teaching Note
Abgenix and the XenoMouse (TN)
Teaching Note for (501-061). View Details
- May 2002 (Revised December 2003)
- Teaching Note
Medicines Company, The TN
Teaching Note for (9-502-006). View Details
- August 2001 (Revised March 2008)
- Case
Helios Health (A)
By: Regina E. Herzlinger and Alfred Martin
Helios PC system provides personalized drug information to the patients in the doctor's waiting room. It has met with considerable consumer acceptance and a very high return for the drug companies that sponsor it. What price should it charge them for the service? View Details
Keywords: Entrepreneurship; Price; Health Care and Treatment; Information Publishing; Innovation and Invention; Product Marketing; Demand and Consumers; Health Industry; Health Industry
Herzlinger, Regina E., and Alfred Martin. "Helios Health (A)." Harvard Business School Case 302-022, August 2001. (Revised March 2008.)
- March 1995 (Revised January 1996)
- Teaching Note
Portfolio Planning at Ciba-Geigy and the Newport Investment Proposal TN
By: David J. Collis
Teaching Note for (9-795-040). View Details
Collis, David J. "Portfolio Planning at Ciba-Geigy and the Newport Investment Proposal TN." Harvard Business School Teaching Note 795-107, March 1995. (Revised January 1996.)
- 2007
- Chapter
Fighting AIDS, Fighting Poverty: Customer Centric Marketing in the Generic Antiretroviral Business
By: Rohit Deshpandé and Zoe Chance
Keywords: Health Disorders; Poverty; Product Marketing; Customers; Pharmaceutical Industry; Pharmaceutical Industry
Deshpandé, Rohit, and Zoe Chance. "Fighting AIDS, Fighting Poverty: Customer Centric Marketing in the Generic Antiretroviral Business." In Business Solutions for the Global Poor: Creating Social and Economic Value, edited by V. Kasturi Rangan, John A. Quelch, Gustavo Herrero, and Brooke Barton. John Wiley & Sons, 2007.
- September 1990 (Revised March 1991)
- Supplement
RU 486 (B)
Describes how Roussel UCLAF resolved the dilemma. Intended for use as an in-class handout. View Details
Badaracco, Joseph L., Jr. "RU 486 (B)." Harvard Business School Supplement 391-051, September 1990. (Revised March 1991.)
- July 1981 (Revised December 1984)
- Case
American Distilling Co. (B)
Fruhan, William E., Jr. "American Distilling Co. (B)." Harvard Business School Case 281-009, July 1981. (Revised December 1984.)
- 21 Nov 2006
- First Look
First Look: November 21, 2006
cost to identify and investigate. The Effect of File Sharing on Record Sales: An Empirical Analysis Authors:Felix Oberholzer-Gee and Koleman Strumpf Periodical:Journal of Political Economy (forthcoming) Abstract For industries ranging... View Details
Keywords: Sean Silverthorne
- 07 Oct 2014
- First Look
First Look: October 7
(MMRC), and brought together a diverse body of academics, researchers, pharmaceutical and biotech companies, physicians, and patients to combine their efforts around the disease. The MMRF had helped facilitate clinical trials for... View Details
Keywords: Sean Silverthorne
- 13 Jan 2009
- First Look
First Look: January 13, 2009
expand internationally with a regional focus on East Asia or, alternatively, a focus on the U.S. and other Western markets. Purchase this case: http://harvardbusinessonline.hbsp.harvard.edu/ b01/en/common/item_detail.jhtml?id=708479 HNA Group: Moving China's Air... View Details
Keywords: Martha Lagace
- January 2017 (Revised March 2017)
- Case
Royal DSM: From Continuous Transformation to Organic Growth
By: William W. George, Carin-Isabel Knoop and Amram Migdal
Royal DSM CEO Feike Sijbesma was pondering the challenges of shifting DSM’s global organization from the constant transformations of the past 100 years to creating organic growth. When Sijbesma took the helm as CEO in 2007, he further pushed and completed the company’s... View Details
Keywords: Organic Growth; Organizational Change; M&A; Mergers And Acquisitions; Divestment; Business Ventures; Business Divisions; Business Growth and Maturation; Restructuring; Change; Change Management; Transformation; Transition; Engineering; Chemicals; Mining; Ethics; Values and Beliefs; Finance; Capital Markets; Financial Markets; Food; Globalization; Global Strategy; Globalized Firms and Management; Globalized Markets and Industries; Health; Nutrition; History; Leadership; Leadership Development; Leadership Style; Leading Change; Management; Business or Company Management; Growth and Development Strategy; Growth Management; Management Practices and Processes; Management Style; Organizations; Corporate Social Responsibility and Impact; Mission and Purpose; Organizational Change and Adaptation; Organizational Culture; Organizational Design; Ownership; Public Ownership; Performance; Strategy; Adaptation; Consolidation; Corporate Strategy; Value; Value Creation; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Europe; Netherlands
George, William W., Carin-Isabel Knoop, and Amram Migdal. "Royal DSM: From Continuous Transformation to Organic Growth." Harvard Business School Case 317-063, January 2017. (Revised March 2017.)
- 19 Aug 2024
- News
Quantum Leap
Subscribe on iTunes Subscribe on Spotify More Skydeck episodes Dan Morrell: Hi, this is Dan Morrell, host of Skydeck. Quantum computing has long been talked about as one of the next big things—the kind of technology, like AI, that will change everything. But to our... View Details
- September 2003 (Revised February 2007)
- Case
PolyMedica Corporation (A)
By: David F. Hawkins and Jacob Cohen
The Securities and Exchange Commission and investors question PolyMedica Corp.'s practice of capitalizing rather than expensing of direct-response advertising. View Details
Keywords: Activity Based Costing and Management; Business Earnings; Advertising; Private Sector; Budgets and Budgeting; Cost Management; Capital Markets; Marketing; Private Equity; Pharmaceutical Industry; Pharmaceutical Industry
Hawkins, David F., and Jacob Cohen. "PolyMedica Corporation (A)." Harvard Business School Case 104-023, September 2003. (Revised February 2007.)
- December 2021
- Case
Zoetis
By: David E. Bell, Damien McLoughlin and Natalie Kindred
- April 1984
- Supplement
Johnson & Johnson (A): Philosophy & Culture, James Burke, Video
By: Francis Aguilar
James Burke, chairman and CEO of Johnson & Johnson, discusses the company's philosophy and culture, with particular emphasis on the significance of the Credo. View Details
Keywords: Organizational Culture; Values and Beliefs; Mission and Purpose; Management Teams; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Aguilar, Francis. "Johnson & Johnson (A): Philosophy & Culture, James Burke, Video." Harvard Business School Video Supplement 884-525, April 1984.
- 07 Jun 2019
- Book
Are You a Digital Manager?
need to build ecosystems, networks with those both inside and outside the organization. We are collecting data on how managers build partnerships, even with other industries, to gain insights into how to drive innovation in their organizations. For instance, a manager... View Details
Keywords: by Martha Lagace